Mark Hurwitz, MD
To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy
Pathologically proven diagnosis of adenocarcinoma of the prostate as confirmed at time of prostatectomy. Post prostatectomy Gleason ≥ 7, baseline PSA nadir ≥ 0.2 ng/ml. Surgical FFPE specimen must be submitted to GenomeDx for genomic analysis on DECIPHER GRID platform per Section 10 of the protocol.
297 (phase II), 612 (phase III)
December 30, 2016
- EMR Pilot template and procedure letter are available are available at NRG-GU002
- The protocol and related documents are available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.